Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 18/20 | 0.82 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.82 |
| ▸ | ESRRG | P62508 | 2/20 | 0.77 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.59 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.59 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.58 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.58 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20806915 | 0.91 | ESR1 (0.78) | ESR1CYP19A1ESRRGESR2 | |
| SCHEMBL30578631 | 0.90 | ESR1 (1.00) | ESR1CYP19A1ESRRGESR2CYP1A2 | |
| SCHEMBL30534784 | 0.90 | ESR1 (1.00) | ESR1CYP19A1ESRRGESR2CYP1A2 | |
| SCHEMBL15669002 | 0.90 | ESR1 (1.00) | ESR1CYP19A1ESRRGESR2CYP1A2 | |
| Endoxifen SCHEMBL10107920 | 0.90 | ESR1 (1.00) | ESR1CYP19A1ESRRGESR2CYP1A2 | |
| Endoxifen SCHEMBL8655920 | 0.90 | ESR1 (1.00) | ESR1CYP19A1ESRRGESR2CYP1A2 | |
| Endoxifen SCHEMBL14391818 | 0.90 | ESR1 (1.00) | ESR1CYP19A1ESRRGESR2CYP1A2 | |
| SCHEMBL9099398 | 0.89 | ESR1 (0.76) | ESR1CYP19A1ESRRGESR2CYP1A2 | |
| SCHEMBL906339 | 0.89 | ESR1 (0.76) | ESR1CYP19A1ESRRGESR2CYP1A2 | |
| SCHEMBL906340 | 0.89 | ESR1 (0.76) | ESR1CYP19A1ESRRGESR2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10968212-B2 | Compounds having estrogen receptor alpha degradation activity and uses thereof | ACCUTAR BIOTECHNOLOGY INC. (US) | 2021-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968212-B2 | Compounds having estrogen receptor alpha degradation activity and uses thereof | ESR2, ESRRG, ESR1 | ESR1 3/4885CYP19A1 7/4885ESRRG 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.